ONC Healthcare IT Certified EHR for Your Medical Practice
Stay on top of your QPP CMS reporting requirements with resources from PrognoCIS EHR compliant solution
PrognoCIS - Compliant with ONC Certifications for Healthcare IT
PrognoCIS Electronic Health Information Export functionality is ONC 2015 Edition Cures Update Certified, which allows users to export the health data for Single Patient or Patient Populations.
ONC Certifications for Healthcare IT – Criteria ‘§170.315(b)(10) Electronic Health Information export PrognoCIS Support’.
PrognoCIS supports 2FA (Two-factor authentication) when a provider prescribes Controlled Substances. This gives additional protection and protects the prescriber from the misuse of the login credentials from inside and external threats.
- ONC Certifications for Healthcare IT – Criteria ‘§170.315(d)(13) Multi-factor authentication PrognoCIS Use Case Support’
- Certified Health IT Product List (CHPL)
- Certification Disclosures
- Compliant with ONC Certifications for Healthcare IT (2014)
Summary of Bizmatic’s Predictive DSI Intervention Risk Management:
- Executive Summary: Bizmatics Intervention Risk Management Practices
- AI Chat Box IRM Summary
- AI Scribe and Scribe Summary IRM Summary
- AI Past Progress Note IRM Summary
Bizmatics has implemented IRM practices to analyze, mitigate, and govern the risk associated with Predictive Decision Support Interventions (Predictive DSIs) that we supply as part of PrognoCIS CEHRT.
Real-World Testing
21st Century Cures Act has introduced ‘§170.405 Real World Testing’(RWT) as a part of Condition and Maintenance of Certification. HIT developers are required to test the certified EHR technology for interoperability to any one or more ONC Certifications for Healthcare IT Criteria, in the type of care settings in which it could be marketed.
Bizmatics submitting PrognoCIS RWT Test Plans and Test Results by the due dates to their ONC-ACB Drummond Group for approval. The approved RWT Test Plans and Test Results will be published on ONC CHPL (Certified Health IT Product List).
- CY 2026 Real World Testing Plan for PrognoCIS
- CY 2025 Real World Testing Plan for PrognoCIS
- CY 2025 Real World Test Result Report for PrognoCIS
- CY 2024 Real World Testing Plan for PrognoCIS
- CY 2024 Real World Test Result Report for PrognoCIS
- CY 2023 Real World Testing Plan for PrognoCIS
- CY 2023 Real World Test Result Report for PrognoCIS
- CY 2022 Real World Testing Plan for PrognoCIS
- CY 2022 Real World Test Result Report for PrognoCIS
Merit-Based Incentive Payment System (MIPS)
MIPS allows providers to earn payment adjustments in 2019 based on their reporting for three categories in 2017:
- Quality
- Improvement Activities &
- Advancing Care Information.
If you see more than 100 Medicare patients or bill more than $30,000 in Medicare Part B, you are eligible to participate in the Quality Payment Program.
Unsure if you qualify? Check your participation status here
On Track for MACRA: The Provider’s Guide to QPP
Ensure your practice is up to speed on reporting requirements for MACRA and MIPS with our latest webinar. View the complete video or jump to the key points below:
1 MIPS Participation (7:35)
2. Pick Your Pace (11:25)
3. MIPS Reporting (15:44)
4. Weightage & Scoring (30:56)
5. Advanced APM Overview (40:51)
6. Meaningful Use/Medicaid (41:27)
7. Appendices (42:19)
8. PrognoCIS Demonstration (44:17)
Ready to explore our EHR ?
What is MACRA?
The Medicare Access & CHIP Reauthorization Act, known as MACRA, presents a new value-based payment system to emphasize patient care. This program combines the Physician Quality Reporting System, Value-Based Modifier, and Meaningful Use to form the Quality Payment Program.
Medicare providers can participate through an Advanced Alternative Payment Model (APM) or the Merit-Based Incentive Payment System (MIPS). The Medicare Access and Chip Reauthorization Act of 2015 (MACRA) aims to reform healthcare by promoting a shift to value-based care.
Let's Connect
Kindly fill in the form, and our dedicated team will be in contact with you soon to discuss further details.
